#pharmaceutical-competition

[ follow ]
fromBusiness Insider
1 week ago

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

Lilly's pill "outperformed" Novo's "on every key endpoint we measured, including A1C and weight loss," lead trial investigator Dr. Julio Rosenstock, an endocrinologist and diabetes and metabolism expert, said in a release.
Healthcare
Business
fromwww.theguardian.com
4 weeks ago

GSK, take two: the bullish tone at the top is finally more convincing | Nils Pratley

GSK's share price returned to its post-merger level after 25 years, indicating cautious investor optimism amid restructuring and leadership-driven changes.
Startup companies
fromFast Company
9 months ago

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down amid market challenges despite leading the company through significant growth in the weight-loss drug sector.
[ Load more ]